It’s a very rewarding trading day for investors in Soligenix (SNGX) with shares up nearly 25%, making the stock Wall Street’s bull of …
Jason McCarthy is out with bullish praise on SNGX now that the biotech player has won its second orphan designation for its RiVax asset.
In a research report issued today, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Soligenix (OTC:SNGX) with a $5 price target, following today’s …
In a research report released today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Soligenix (SNGX) with a $3 price target, …
